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Introduction {#sec1}
============

Ischemic heart disease resulting in myocardial infarction (MI) remains one of the most common causes of mortality worldwide. Although some reports have indicated that adult human cardiomyocytes possess the capacity to proliferate at a very low rate ([@bib5], [@bib6]), this limited capacity is insufficient to compensate for the massive loss of cardiomyocytes that occurs upon MI. Instead, injury activates a fibrotic response that generates a non-contractile scar that impairs normal heart function. Thus, the ability to generate new cardiomyocytes represents an important therapeutic goal, and many recent studies have proposed different strategies to achieve this goal. Cellular transplantation of cardiac progenitor cells, stem cells, or in vitro stem cell-derived cardiomyocytes holds clinical potential, but cell therapy is, so far, relatively inefficient due to failure of stem cells to fully adopt a functional contractile phenotype, insufficient mechanical and electrophysiological integration into the myocardium, and inadequate long-term retention of transplanted cells in the heart ([@bib46]). Therefore, there is a major need to develop new therapeutic strategies that eliminate the obstacles facing current therapies for post-MI cardiac repair.

During the last decade, cellular reprogramming has emerged as a promising strategy for regenerative medicine. In 2010, the cardiac transcription factors GATA4, MEF2C, and TBX5 were shown to be capable of converting mouse fibroblasts into cardiomyocyte-like cells in vitro (induced cardiac-like myocytes \[iCLMs\]) ([@bib22]). Soon thereafter, cardiac reprogramming was achieved in human cells ([@bib37], [@bib53]) and several variations on the original cocktail of transcription factors were found to enhance reprogramming efficiency ([@bib1], [@bib10], [@bib20], [@bib25], [@bib42], [@bib50], [@bib57]; reviewed in [@bib4]). Conversion of fibroblasts into cardiomyocytes in vivo has also been shown to improve cardiac function following MI in mice ([@bib43], [@bib50]). Very recently, it has been shown that cardiac reprogramming can be achieved by a purely chemical approach, avoiding the introduction of foreign genetic material ([@bib8]). Despite the great potential of these discoveries, cardiac lineage conversion remains relatively inefficient and the underlying molecular mechanisms have not been fully elucidated.

The Notch pathway is an evolutionarily conserved signaling pathway that regulates cell-fate specification, differentiation, and developmental patterning ([@bib19]). Notch is a single-pass transmembrane receptor that is activated upon cell-cell contact, as a result of its interaction with ligands (Jagged or Delta). In mammals, four Notch receptors (Notch 1--4) and five transmembrane ligands (Jagged 1, Jagged 2, Delta-like 1, Delta-like 3, and Delta-like 4) have been identified. Upon activation, the Notch receptor undergoes two sequential cleavages, first by a metalloprotease (ADAM) on its extracellular domain and, subsequently, by a γ-secretase enzyme complex that triggers the release of the Notch intracellular domain (NICD) and its translocation to the nucleus ([@bib3]). In the canonical Notch pathway, NICD binds to the transcription factor RBPJ-k in the nucleus, displaces co-repressors, and allows the recruitment of co-activators to target gene promoters, leading to transcriptional activation. Typical target genes include those encoding basic-helix-loop-helix repressors of the Hes and Hey families. However, there are several reports supporting the existence of a "non-canonical" Notch pathway, which functions independently of RBPJ-k. Interestingly, Notch activity impairs myoblast differentiation independently of RBPJ-k (reviewed in [@bib2]), in part by blocking the binding of the transcription factor MEF2C to chromatin ([@bib55]). In the heart, the Notch signaling pathway plays a critical role during development by regulating cell fate and cardiomyocyte proliferation. Accordingly, mutations that affect this signaling pathway are linked with congenital heart disease (reviewed in [@bib11]). However, there is conflicting evidence regarding the role of Notch in cardiac differentiation, showing that Notch activation can both promote and inhibit cardiomyocyte differentiation ([@bib24], [@bib9], [@bib27], [@bib29]). The potential influence of Notch signaling on the reprogramming of fibroblasts to iCLMs has not yet been explored.

Here, we show that inhibition of Notch signaling by the γ-secretase inhibitor DAPT ((S)-tert-butyl 2-((S)-2-(2-(3,5-difluorophenyl)acetamido)propanamido)-2-phenylacetate) enhances the reprogramming of mouse fibroblasts to iCLMs, at least in part by increasing the binding of MEF2C to cardiac gene promoters. These findings provide insights into the molecular basis of cardiac lineage conversion and provide a chemical approach to improve the efficiency of this technique.

Results {#sec2}
=======

DAPT, a γ-Secretase Inhibitor, Enhances Cardiac Reprogramming by GHMT {#sec2.1}
---------------------------------------------------------------------

We showed previously that GATA4, HAND2, MEF2C, and TBX5 (hereafter GHMT) can reprogram fibroblasts to iCLMs ([@bib50]). In an effort to improve the efficiency of this process, we screened a collection of seven chemical compounds that were previously shown to promote reprogramming of fibroblasts to induced pluripotent stem cells ([Table S1](#mmc1){ref-type="supplementary-material"}) ([@bib7], [@bib14], [@bib15], [@bib21], [@bib30], [@bib34], [@bib48]). Mouse embryonic fibroblasts (MEFs) were isolated from transgenic mice that express GFP under the control of the cardiac α-myosin heavy chain promoter (αMHC-GFP), and reprogramming was induced by transducing the cells with retroviruses encoding for GHMT. After retroviral transduction, the medium was changed to cardiomyocyte induction medium containing DMSO or various chemicals ([Table S1](#mmc1){ref-type="supplementary-material"}). After 7 days of induction, the generation of iCLMs was scored by the presence of GFP-positive cells ([Figure 1](#fig1){ref-type="fig"}A). The γ-secretase inhibitor DAPT, a well-established inhibitor of Notch signaling, was the most efficient compound tested, approximately doubling the number of GFP-positive cells after 7 days of reprogramming ([Figure 1](#fig1){ref-type="fig"}B).

To further characterize the role of Notch inhibition in cardiac reprogramming, we performed optimization experiments by varying the concentration of DAPT (2.5, 5, and 10 μM) and the time period of treatment. Optimized conditions were determined to be 2.5 μM DAPT with continuous exposure for a 2-week period ([Figure S1](#mmc1){ref-type="supplementary-material"}). DAPT treatment significantly increased the number of iCLMs, measured by the expression of cardiomyocyte-specific genes ([Figure 1](#fig1){ref-type="fig"}C) and by immunostaining for the cardiomyocyte markers cardiac troponin T (cTnT) and α-actinin ([Figures 1](#fig1){ref-type="fig"}D and 1E). We performed proliferation analysis by flow cytometry after 7 days of reprogramming and determined that DAPT treatment does not affect the proliferation of iCLMs (cTnT-positive cells) or fibroblasts (cTnT-negative cells); therefore, the increase in the number of iCLMs is not due to a DAPT effect on proliferation ([Figure S2](#mmc1){ref-type="supplementary-material"}A). To confirm our observations, we tested dibenzazepine (DBZ), a structurally unrelated γ-secretase inhibitor, and found that DBZ was also able to enhance reprogramming, although to a lesser extent than DAPT, at least at the concentration tested (10 μM) ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). In addition, the effect of DAPT was tested on reprogramming of adult tail-tip fibroblasts (TTFs), and similar reprogramming enhancement was observed ([Figure S2](#mmc1){ref-type="supplementary-material"}D).

DAPT Increases Calcium Flux, Sarcomere Structure, and Spontaneous Beating of iCLMs {#sec2.2}
----------------------------------------------------------------------------------

To determine whether DAPT enhances cardiomyocyte features, we assessed sarcomere structure. In the presence of GHMT, DAPT induced a 5-fold increase in the number of cells with an organized sarcomere structure ([Figures 1](#fig1){ref-type="fig"}F and 1G). Moreover, although GHMT-reprogrammed cells rarely show spontaneous beating at 25 days, treatment with DAPT induced a 6-fold increase in the number of spontaneously beating cells ([Figure 1](#fig1){ref-type="fig"}H). To analyze calcium flux, we used two different methods: a calcium reporter system (αMHC-Cre/Rosa26-Flox-Stop-Flox-GCaMP3 MEFs) for live cell imaging ([Figure S3](#mmc1){ref-type="supplementary-material"}), and the fluorescent calcium indicator dye 4-Fluo AM. Both methods showed that DAPT treatment significantly increased the number of cells with calcium flux ([Figures 1](#fig1){ref-type="fig"}I and 1J).

To assess transcriptional events prior to the acquisition of spontaneous beating, we performed RNA-sequencing (RNA-seq) analysis of MEFs infected with GHMT and treated with vehicle (DMSO) or DAPT for 15 days ([Table S2](#mmc1){ref-type="supplementary-material"}). Using a fold change cutoff of 1.5 and a false discovery rate of \<0.01, 115 differentially expressed genes were identified, 27 of which were upregulated and 88 downregulated in GHMT cells treated with DAPT ([Figure 2](#fig2){ref-type="fig"}A; [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). Among the upregulated genes we found numerous cardiomyocyte-related genes, such as *Myh6*, *Actc1*, *Actn2*, *Pln*, *Myh7*, and *Myl1* ([Table S3](#mmc1){ref-type="supplementary-material"}). DAPT did not enhance the expression of the GHMT reprogramming factors. Gene ontology analysis showed that most of the significantly increased biological processes were related to muscle and heart physiology, cardiac and muscle differentiation, and excitation-contraction coupling ([Figure 2](#fig2){ref-type="fig"}B). Moreover, DAPT treatment of GHMT-expressing cells efficiently upregulated cardiomyocyte-related genes and downregulated fibroblast genes ([Figure 2](#fig2){ref-type="fig"}C). Similarly, using the gene set enrichment analysis (GSEA) computational method, we obtained a highly significant upregulation of gene sets related to cardiomyocytes, such as "muscle contraction" and "respiratory electron transport" gene sets, and a clear downregulation of the "cycling genes" set ([Figures 2](#fig2){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}).

DAPT Cooperates with AKT1 to Enhance Cardiac Reprogramming {#sec2.3}
----------------------------------------------------------

Previously, we showed that protein kinase AKT1 enhances cardiac reprogramming through mTOR and FOXO3A ([@bib57]). We tested whether DAPT cooperates with AKT1 during cardiac reprogramming by infecting αMHC-GFP MEFs with GHMT plus AKT1 (AGHMT), and treating the cells with vehicle or DAPT. Notably, AKT1 and DAPT together increased reprogramming efficiency up to 70%, as revealed by immunostaining against cTnT and α-actinin ([Figures 3](#fig3){ref-type="fig"}A and 3B). In addition, DAPT treatment of AGHMT cells increased the number of cells with calcium flux ([Figure 3](#fig3){ref-type="fig"}C). Moreover, 18 days after AGHMT infection, 40% of the cells treated with DAPT displayed spontaneous beating in culture ([Figure 3](#fig3){ref-type="fig"}D). Given this striking effect, we analyzed by western blot the expression of the ryanodine receptor and the ER Ca^2+^-ATPase SERCA2, both critical regulators of intracellular calcium handling and contractility. Expression of both proteins was increased by DAPT treatment, reaching higher levels than with AGHMT alone ([Figure 3](#fig3){ref-type="fig"}E). We conclude that DAPT cooperates with AKT1 to boost cardiac reprogramming.

Inhibition of the Canonical Notch Pathway Does Not Enhance Cardiac Reprogramming {#sec2.4}
--------------------------------------------------------------------------------

By RNA-seq analysis, we surprisingly noted that none of the most common Notch target genes were downregulated by DAPT. As shown in [Table S4](#mmc1){ref-type="supplementary-material"}, this was seen for the Hes/Hey gene family and the Notch target genes *c-Myc* and *p21*. Consistently, these data were validated by qPCR ([Figure 4](#fig4){ref-type="fig"}A). Moreover, using GSEA several gene sets related to the canonical Notch pathway were analyzed, none of which were downregulated in DAPT-treated samples ([Figure 4](#fig4){ref-type="fig"}B). However, among the downregulated genes there were two genes that have been previously described as Notch targets: *Skp2* ([@bib12], [@bib13], [@bib47]) and *IL33* ([@bib52]). SKP2 is a component of the ubiquitin protein ligase complex SCF, and specifically recognizes the phosphorylated cyclin-dependent kinase p27 to promote its degradation. Given that p27 is known to be involved in cell-cycle arrest and cell differentiation, we tested whether DAPT could enhance reprogramming by increasing the protein levels of p27. However, western blot analysis indicated that p27 protein levels were decreased, rather than increased, upon DAPT treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}A), and cardiac reprogramming was enhanced, rather than impaired, in p27 knockout MEFs compared with wild-type MEFs ([Figure S5](#mmc1){ref-type="supplementary-material"}B).

IL33, a member of the interleukin-1 family, resides in the nucleus bound to chromatin where it modifies transcription by undefined mechanisms. However, IL33 is released from cells upon tissue injury, inducing an inflammatory response. We validated by qPCR and ELISA the reduction of *IL33* in GHMT-DAPT samples ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D), but did not see a decrease in reprogramming efficiency when recombinant IL33 protein was added to the reprogramming medium ([Figure S5](#mmc1){ref-type="supplementary-material"}E), or an increase in reprogramming upon *IL33* downregulation by small hairpin RNAs (shRNAs) ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F); therefore, IL33 does not seem to play an important role in cardiac reprogramming.

To test whether RBPJ-k, a major downstream regulator of the canonical Notch pathway, mediated the effects of DAPT, we inhibited *Rbpj-k* expression by shRNAs, achieving a 70% reduction in mRNA expression ([Figure 4](#fig4){ref-type="fig"}C). Decrease of *Rbpj-k* expression did not improve cardiac reprogramming mediated by GHMT, as measured by qPCR and immunostaining of different cardiac markers ([Figures 4](#fig4){ref-type="fig"}D and 4E). We conclude that inhibition of the canonical Notch pathway is not responsible for the enhancement of reprogramming by DAPT.

DAPT Enhances MEF2C Binding to Cardiac Gene Promoters {#sec3}
=====================================================

Notch activation is known to impair myoblast differentiation ([@bib49], [@bib55]). We previously showed that this effect is due, at least in part, to the interaction of NICD with the MEF2C DNA binding domain, which reduces MEF2C binding to chromatin, thereby decreasing expression of MEF2C target genes ([@bib55]). To examine whether Notch has a similar role in cardiac reprogramming, we overexpressed NICD in MEFs during reprogramming and found that it impaired cardiac reprogramming by GHMT, as seen by qPCR and immunostaining ([Figures 5](#fig5){ref-type="fig"}A and 5B). To analyze whether DAPT treatment and the subsequent decrease in NICD affects the binding of MEF2C to its target genes, we analyzed the promoter regions of the cardiac genes that were differentially regulated by DAPT using our RNA-seq data ([Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). We performed chromatin immunoprecipitation (ChIP) using an MEF2C antibody in MEFs infected with GHMT and treated or untreated with DAPT. Using qPCR, we analyzed MEF2C binding to specific promoter regions in the presence or absence of DAPT. Our results showed that addition of DAPT substantially increased the binding of MEF2C to the promoter of the *Myh6*, *Tnnt2*, and *Actc1* genes ([Figure 5](#fig5){ref-type="fig"}C). Importantly, this increase in binding was not due to an induction of MEF2C protein by DAPT, as demonstrated by western blot analysis ([Figure 5](#fig5){ref-type="fig"}D). These observations suggest that Notch inhibition results in full activation of the cardiac differentiation factor MEF2C, thus providing a mechanistic explanation for the effects of DAPT on cardiac reprogramming.

Discussion {#sec4}
==========

Heart failure remains the primary cause of mortality and morbidity worldwide, and cardiac reprogramming represents a new approach to cardiac repair. Although this technique has been significantly improved over the past 5 years, some barriers still remain for its clinical translation, including the poor efficiency of conversion and the failure to create consistent populations of mature contractile cells ([@bib45]). In the present study, we demonstrate that the γ-secretase inhibitor DAPT promotes cardiac reprogramming from mouse fibroblasts to induced cardiomyocytes, not only by increasing the number of induced cardiomyocytes but also by producing a remarkable increase in the number of spontaneously beating cells. Accordingly, DAPT treatment induces the formation of an advanced sarcomere structure and increased calcium flux.

Our results suggest that the Notch signaling pathway is active during the cardiac reprogramming process, which is consistent with Notch having a critical role during heart development by regulating cardiomyocyte cell fate and proliferation (reviewed in [@bib11]). Our results are in line with previous studies reporting that Notch inactivation promotes cardiac differentiation from pluripotent stem cells ([@bib24], [@bib40]). Conversely, other reports suggest that Notch activation is important for cardiac lineage differentiation in other progenitor cell types ([@bib9], [@bib27], [@bib29]), and it has been suggested that Notch favors or impairs differentiation in a cell-type- and time-specific manner ([@bib32]). In fact, Notch inactivation could have different effects depending on the reprogramming strategy; some studies have already reported different chemical strategies to improve cardiac reprogramming ([@bib8], [@bib23], [@bib54]), but the role of the Notch pathway during cardiac reprogramming has not been reported. Regarding its role in vivo, some reports indicate that activation of Notch signaling has a cardioprotective role after heart injury ([@bib17], [@bib18]), but to our knowledge Notch inactivation has not been coupled, so far, with cardiac reprogramming as a cardiac repair strategy.

When combined with AKT1, during GHMT-mediated reprogramming we revealed that DAPT induces up to 70% conversion efficiency, with ∼45% of reprogrammed cells displaying spontaneous beating. Previously, we reported that AKT1 enhances reprogramming through mTORC1 and FOXO3A ([@bib57]). We examined whether DAPT could enhance reprogramming by the activation of the phosphatidylinositol 3-kinase (PI3K)-AKT1 pathway, but did not observe any increase in Akt activation upon DAPT treatment (data not shown). Notch inhibition and AKT1 seem to employ independent but cooperative mechanisms to boost the production of iCLMs by GHMT. Given that the inefficiency of the cardiac reprogramming process is an important limitation, these results represent a significant advance over other existing lineage conversion techniques.

In agreement with our functional assays, transcriptome analysis by RNA-seq showed that DAPT treatment induces genetic programs related to muscle development, differentiation, and excitation-contraction coupling, and at the same time downregulates genetic programs related to cell proliferation. Of note, no gene set related to the Notch canonical pathway was significantly downregulated, and downregulation of Rbpj-k, a main downstream Notch regulator, did not produce a significant effect on cardiac reprogramming, so we conclude that the Notch canonical pathway is not responsible for DAPT enhancement of reprogramming. However, we have shown that NICD overexpression impairs GHMT-mediated reprogramming. By ChIP experiments, we demonstrated that MEF2C binds to the promoter of the cardiac genes *Myh6*, *Tnnt2*, and *Actc1*, and that this binding is enhanced by DAPT treatment. These results are in line with our previous observations that NICD blocks the binding of MEF2C to chromatin and suppresses its transcriptional activity in myotubes ([@bib55]). Interestingly, it has been demonstrated that the co-transcriptional activator MAML binds to MEF2C to promote myotube differentiation and NICD blocks MEF2C-MAML binding, impairing differentiation ([@bib49]). In light of this and our current findings, we propose a mechanistic model in which DAPT treatment results in Notch inhibition and, consequently, full activation of MEF2C transcriptional activity on cardiac gene promoters ([Figure 5](#fig5){ref-type="fig"}E), although we recognize that it is possible that other mechanisms may contribute to this process.

Cardiac reprogramming constitutes a promising strategy for heart repair. Since it was described in 2010, several signaling pathways have been demonstrated to affect this process, such as transforming growth factor β ([@bib23]), Wnt ([@bib28]), and PI3K-AKT ([@bib57]) pathways. Changing the cell fate (in this case from fibroblasts to cardiomyocytes) is a complex and tightly regulated process whereby many different pathways, acting at different levels, must be orchestrated to first lose the initial cell identity and successfully adopt a different one. The finding that Notch inactivation by DAPT promotes cardiac reprogramming provides a "druggable" inroad into the reprogramming process. It will be of clinical interest to test whether Notch inactivation favors cardiac reprogramming in vivo in the context of a myocardial infarct, mediated either by transcription factors or purely by chemicals. Of note, Notch inhibitors are currently in several preclinical and clinical trials for cancer treatment ([@bib56]). Although cellular reprogramming as a regenerative strategy still faces many challenges, our findings represent a significant advance in terms of efficiency and quality of cardiac reprogramming, as well as a better understanding of the molecular mechanisms that govern this process.

Experimental Procedures {#sec5}
=======================

All experiments involving animals were approved by the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center.

Cell Culture {#sec5.1}
------------

Wild-type, αMHC-GFP transgenic ([@bib50]), or p27 knockout ([@bib16]) MEFs and wild-type TTFs were isolated as described by [@bib38], and cultured in DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The following chemical compounds were added to the induction medium: 2.5 μM DAPT (Selleckchem); 10 μM DBZ (Selleckchem); 2 μM 616452 (Calbiochem); 5 μM GO 6983 (Sigma); 10 ng/μL L-ascorbic acid (Sigma); 1 μM OAC2 (Sphinx Scientific); 100 nM JQ1 (BPS Bioscience); 10 ng/mL human interleukin-6 (Life Technologies); or 10 μg/mL recombinant mouse IL33 protein (R&D Systems).

Mouse Adult Cardiomyocyte Isolation {#sec5.2}
-----------------------------------

Adult mouse cardiomyocytes were isolated as described previously ([@bib35]). Anesthesia was induced using 3% isoflurane and maintained using 1% isoflurane. Mouse hearts were rapidly excised and the aorta was cannulated on a constant-flow Langendorff apparatus. The heart was digested by perfusion of Tyrode\'s solution containing 0.2 mg/mL Liberase DH (Roche) and 0.02 mM CaCl~2~, 10 mM glucose, 5 mM HEPES, 5.4 mM KCl, 1.2 mM MgCl~2~, 150 mM NaCl, and 2 mM sodium pyruvate (pH 7.4). When the tissue softened, the left ventricle was isolated and gently minced, filtered, and equilibrated in Tyrode\'s solution with 200 μM CaCl~2~ and 1% BSA at room temperature.

Cardiac Reprogramming, Beating Cell Analysis, and Calcium Flux Measurements {#sec5.3}
---------------------------------------------------------------------------

Generation of retroviral constructs of mouse *Gata4*, *Hand2*, *Mef2c*, *Tbx5*, and *Akt1* has been previously described ([@bib50], [@bib57]). The retroviral constructs for the expression of shRNAs targeting *Rbpj-k* and *IL33* were purchased from Origene. 293T cells were transiently transfected using Fugene6 with 4 μg of pCLEco (which express the viral genes *gag*, *pol* and *envEco*) and 4 μg of the vector of interest. Forty-eight hours later, the supernatant containing the viral particles was collected and filtered, and polybrene was added to a final concentration of 8 μg/mL. This supernatant was added to the fibroblasts (MEFs or TTFs), seeded the previous day at a concentration of 7,500 cells/cm^2^. This procedure was repeated 12 hr and 24 hr later. Forty-eight hours later, viral medium was replaced with induction medium, composed of DMEM/199 (4:1), 10% FBS, 5% horse serum, 1% penicillin/streptomycin, 1% non-essential amino acids, 1% essential amino acids, 1% B-27, 1% insulin-selenium-transferrin, 1% vitamin mixture, and 1% sodium pyruvate (Invitrogen). The medium was changed every 2 days until the cells were harvested. Beating cell analyses were performed as described by [@bib57]. For calcium flux measurements, cells were loaded with 5 μM Fluo-4 AM (Molecular Probes), or we used αMHC-Cre/Rosa26A-Flox-Stop-Flox-GCaMP3 MEFs and calcium flux was quantified as described in [@bib57].

Immunocytochemistry {#sec5.4}
-------------------

Cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.2% Triton X-100 in PBS for 15 min at room temperature. Cells were blocked with 10% goat serum in PBS for 1 hr and then incubated with primary antibodies against cTnT (mouse monoclonal, Thermo Scientific, MS-295-P; 1:400), α-actinin (mouse monoclonal, Sigma, A7811; 1:400), and GFP (A11122, Life Technologies) for 2 hr at room temperature followed by incubation with appropriate Alexa fluorogenic secondary antibodies (Invitrogen) at room temperature for 1 hr.

Proliferation Assays {#sec5.5}
--------------------

Wild-type MEFs were infected with GHMT and treated with 2.5 μM DAPT or DMSO for 7 days. We analyzed the proliferation using the Click-iT Edu Flow Cytometry Assay Kit (Invitrogen), treating with 20 μM 5-ethynyl-2′-deoxyuridine for 24 hr and following the manufacturer\'s protocol.

Quantitative mRNA Measurement, Western Blot Analysis, and ELISA {#sec5.6}
---------------------------------------------------------------

Total RNA was extracted using TRIzol (Invitrogen) following the provider\'s recommendations and retrotranscribed into cDNA using iScript Supermix (Bio-Rad) following the manufacturer\'s instructions. Real-time qPCR was performed using Taq-man probes (Applied Biosystems) for *Tnnt2*, *Myh6*, and *Actc1*, and Kapa Sybr Fast (Kapa Biosystems) for *IL33* using the primers *Fw* 5′-TCC AAC TCC AAG ATT TCC CCG-3′ and *Rv* 5′-CAT GCA GTA GAC ATG GCA GAA-3′. For input normalization, we used *Gapdh Fw* 5′-AGG TCG GTG TGA ACG GAT TTG-3′ and *Rv* 5′-TGT AGA CCA TGT AGT TGA GGT CA-3′. Western blot analyses were performed as described by [@bib39], using SERCA2 ATPase antibody (1:1,000, MA3-919, Thermo Scientific), ryanodine receptor antibody (1:1,000, MA3-916, Thermo Scientific), and MEF2C antibody (1:500, ab79436, Abcam). ELISA was performed using Mouse IL33 DuoSet from R&D.

RNA-Seq and Transcriptome Analysis {#sec5.7}
----------------------------------

Total RNA was isolated using TRIzol following the provider\'s instructions. Illumina RNA-seq was performed by the University of Texas Southwestern Microarray Core Facility. Quality assessment of the RNA-seq data was done using the NGS QC Toolkit ([@bib41]) with default setting. Quality filtered reads generated by the tool were then aligned to the mouse reference genome GRCm38 (mm10) using the TopHat2 (v. 2.0.0) aligner ([@bib26]) using default settings. Differential gene expression analysis was done using the R package DESeq (v. 1.6.3) ([@bib33]). Read counts obtained from featureCounts ([@bib31]) were normalized by taking the median of each gene count across samples and dividing each sample gene count by the relative ratio of library sizes between the calculated median and sample size. The averaged normalized expression values of the samples were used to calculate fold change and p values. Cutoff values of fold change greater than 1.5 and p values less than 0.05 were then used to select for differentially expressed genes between sample group comparisons. Significant pathway enrichment analysis was performed using PANTHER Overrepresentation Test (release 20150430, <http://geneontology.org>). Notch pathways were extracted from MSigDB ([@bib51]) and enrichment plots were performed using GSEA ([@bib36]).

Chromatin Immunoprecipitation {#sec5.8}
-----------------------------

ChIP assays were performed as previously described ([@bib44]), with some modifications. In brief, cells were crosslinked with 1% formaldehyde-PBS for 15 min with constant shaking, and formaldehyde was neutralized by the addition of glycine to a final concentration of 0.125 M for another 5 min. Cells were washed with cold PBS and collected in 300 μL of Chip Whole Lysis Buffer (10 mM Tris-HCl \[pH 8.0\], 10 mM NaCl, 3 mM MgCl~2~, 0.5% NP-40, 1% SDS, and 0.5% sodium deoxycholate). Chromatin fragmentation was performed by sonication using a Diagnode BioRupter (three cycles of 7.5 min with 30 s on/off). Protein concentration was quantified and 450 μg were immunoprecipitated by using 3 μg of anti-MEF2C (ab79436, Abcam). The antibody/chromatin complexes were rotated end-to-end overnight at 4°C. Antibody/chromatin complexes were pulled down using Dynabeads protein G-conjugated magnetic beads (Life Technologies). Chromatin was washed, eluted, and reverse-crosslinked. Chromatin fragments were then analyzed by qPCR using SYBR Green fluorescence. Primers are available upon request.

Statistical Analysis {#sec5.9}
--------------------

Statistical significance was determined using the Student\'s t test (unpaired two-tailed). All data are presented as mean ± SD (error bars). For every reprogramming experiment, three different plates per group were reprogrammed in parallel (n = 3 biological replicates). Representative reprogramming experiments (out of at least three experiments) are shown, unless otherwise specified. Significance in figures is depicted by ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.
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![DAPT Increases Calcium Flux, Sarcomere Structure, and Spontaneous Beating in iCLMs\
(A) Experimental strategy for drug screening to enhance cardiac reprogramming.\
(B) Quantification of the number of αMHC-GFP-positive MEFs after 7 days of reprogramming by GHMT and treatment with the indicated chemicals. Values are shown as relative to the mock control; n = 3 biological replicates.\
(C) αMHC-GFP MEFs were infected with GHMT, and treated with DMSO or DAPT for 2 weeks. Analysis by qPCR of the mRNA expression of the indicated genes, relative to expression in DMSO-treated cells; n = 3 biological replicates.\
(D) Quantification of the number of cells positive for cTnT and α-actinin by immunostaining; n = 3 biological replicates.\
(E) Representative image of the immunostaining quantified in (D). Scale bar, 200 μm.\
(F) Representative confocal images of immunostaining against α-actinin showing sarcomere structure in iCLMs (treated with DMSO or DAPT) and mouse adult cardiomyocytes. The percentage of cells presenting a sarcomere structure is shown in the upper-right corner of every panel. Scale bar, 20 μm.\
(G) Quantification of the percentage of α-actinin-positive cells with sarcomeric structure. The average of three different experiments is shown, with a total n = 471 in vehicle-treated cells and n = 570 in DAPT-treated cells.\
(H) Percentage of beating cells, relative to the number of input cells at indicated times; n = 3 biological replicates.\
(I) Quantification of Ca^2+^ flux-positive GCaMP3 cells after 2 weeks of reprogramming; n = 3 biological replicates.\
(J) Quantification of Ca^2+^ flux-positive MEFs treated with 4-Fluo AM dye after 2 weeks of reprogramming; n = 3 biological replicates.\
Data are presented as mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01. See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![DAPT Treatment Induces Genetic Programs Related to Muscle Development, Differentiation, and Excitation-Contraction Coupling\
RNA-seq was performed on MEFs infected with GHMT and treated for 15 days with DMSO (vehicle) or DAPT.\
(A) Heatmap generated with differentially expressed genes.\
(B) Graphical representation of gene ontology analysis using PANTHER Overrepresentation Test.\
(C) Hierarchical clustering and heatmap using cardiomyocyte- and fibroblast-specific genes.\
(D) Enrichment plots of the indicated gene sets and their nominal p values. See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Tables S2--S4](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Notch Inhibition Cooperates with AKT1 to Enhance Cardiac Reprogramming\
αMHC-GFP MEFs (or GCaMP MEFs in C) were infected with GHMT or AGHMT, and treated with DMSO (vehicle) or DAPT.\
(A) Representative immunostaining images of GFP, α-actinin, and cTnT at day 15 of reprogramming. Scale bar, 200 μm.\
(B) Quantification of cells positive for α-actinin and cTnT as determined by immunostaining; n = 3 biological replicates.\
(C) Quantification of Ca^2+^ flux-positive cells in GCaMP MEFs at day 15; n = 3 biological replicates.\
(D) Percentage of beating cells, relative to the number of input cells; n = 3 biological replicates.\
(E) Immunoblot against the Ca^2+^ handling proteins ryanodine receptor (RyR) and SERCA2 at day 15 of reprogramming. Densitometric quantification is shown as the average of every replicate, relative to GAPDH.\
Data are presented as mean ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.](gr3){#fig3}

![Inhibition of the Canonical Notch Pathway Does Not Enhance Reprogramming\
(A) qPCR analysis of Notch target genes in MEFs reprogrammed by GHMT, at day 15; n = 3 biological replicates.\
(B) Enrichment plots of Notch pathways gene sets, and its nominal p value.\
(C--E) αMHC-GFP MEFs were infected with GHMT and an shRNA scramble (scr) or an shRNA against *Rbpj-k*. At day 15, *Rbpj-k* mRNA expression was analyzed by qPCR (C), and different cardiac markers were analyzed by qPCR (D) or by immunostaining (E); n = 3 biological replicates. Scale bar, 100 μm.\
Data are presented as means ± SD. ^∗∗∗^p \< 0.001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![NICD Inhibition Increases the Transcriptional Activity of MEF2C at Cardiac Gene Promoters\
(A and B) αMHC-GFP MEFs were infected with GHMT, or GHMT + NICD, and treated or untreated with DAPT. At day 15, different cardiac markers were analyzed (A) by immunostaining or (B) by qPCR; n = 3 biological replicates. Scale bar, 100 μm.\
(C and D) MEFs were infected with empty vector or GHMT, and treated with vehicle (DMSO) or with DAPT for 15 days. (C) Chromatin immunoprecipitation of MEF2C followed by qPCR of the indicated genomic regions. An exonic region of *Actc1* was used as a control; n=3, three independent immuoprecipitations. (D) Immunoblot using MEF2C antibody. Densitometric quantification, relative to GAPDH, is shown.\
(E) Model illustrating proposed molecular mechanism by which Notch inhibition enhances cardiac reprogramming.\
Data are presented as means ± SD. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.](gr5){#fig5}
